Safety of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials

Katharina Doni  
University of Cologne: Universitat zu Koln

Stefanie Bühn  
Witten/Herdecke University

Alina Weise  
Witten/Herdecke University

Nina-Kristin Mann  
Universität Witten/Herdecke: Universitat Witten/Herdecke

Simone Hess  
Witten/Herdecke University

Andreas Sönnichsen  
Medical University of Vienna: Medizinische Universitat Wien

Dawid Pieper  
University Witten/Herdecke

Petra Thürmann  
University Witten/Herdecke

Tim Mathes (✉ Tim.Mathes@uni-wh.de)  
University Witten/Herdecke  https://orcid.org/0000-0002-5304-1717

Research Article

Keywords: Older patients, direct anti-coagulants, systematic review, meta-analyses

DOI: https://doi.org/10.21203/rs.3.rs-445458/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Purpose**

Our objective was to assess the safety of long-term intake of DOACs in older adults with atrial fibrillation (AF).

**Methods**

We included RCTs in elderly (≥ 65 years) patients with AF. A systematic search in MEDLINE and EMBASE was performed on 9/11/2020. For determination of risk of bias, the RoB-2 tool was applied. We pooled outcomes using random-effects meta-analyses. The quality of evidence was assessed using GRADE.

**Results**

Ten RCTs with a total of 61,948 patients were identified. Seven RCTs included patients with AF-only and three with AF who received PCI and additional antiplatelet-therapy. Two RCTs compared apixaban with either warfarin or aspirin, three edoxaban with either placebo, aspirin, or Vitamin K antagonists (VKAs), two dabigatran with warfarin and three rivaroxaban with warfarin.

DOACs probably reduce mortality in elderly patients with AF-only (HR 0.89 95%CI 0.78 to 1.02). We did not find any RCT that reported mortality in elderly AF-PCI patients. Low-dose DOACs likely reduce bleeding compared to VKAs (HR ranged from 0.47 to 1.01). High-dose edoxaban reduces major or clinically relevant bleeding (MCRB) compared to VKAs (HR 0.82 95%CI 0.73 to 0.93) but high-dose dabigatran or rivaroxaban increase MCRB (HR 1.15 95%CI 1.02 to 1.30).

**Conclusion**

We found that low-dose DOACs probably decrease mortality in AF-only patients. Moreover, apixaban and edoxaban are associated with fewer MCRB compared to VKAs. For dabigatran and rivaroxaban, the risk of MCRB varies depending on dose.

**Introduction**

Balancing stroke prevention and risk of bleeding in patients with atrial fibrillation (AF) is challenging. Vitamin K antagonists (VKA) have been the main treatment for stroke prevention in AF patients in the past. However, the huge inter-individual variability of the clinical response, the necessity of monitoring the INR (International Normalized Ratio) and the quite unmanageable spectrum of food and drug interactions are major disadvantages of VKAs [1].

In the last decade, various direct oral anticoagulants (DOACs) entered the market which aimed to overcome these disadvantages. Randomized controlled trials (RCTs) on DOACs, namely rivaroxaban, apixaban, dabigatran, and edoxaban have shown a positive benefit-risk profile [2–9]. DOACs are by now considered the standard of care for treating patients with AF in international guidelines [10, 11].
Various patient related factors, in particular renal dysfunction, hepatic impairment and body weight can impact the pharmacokinetics of DOACs and consequently the risk for adverse events, such as major bleeding [12]. Studies under routine care conditions indicate that the real-world population differs from the one in RCTs with respect to these characteristics. These differences could have a significant impact on the benefit-risk ratio of DOACs [13]. Most conspicuous is that the population in real-world data-based studies is about ten years older than in RCTs [14–18]. As pharmacokinetics of DOACs are different in older adults when compared to younger patients, safety analysis of DOAC use in the elderly is of major interest [19].

A systematic review of RCTs and observational studies suggest superior effectiveness and similar safety of DOACs compared to VKAs and that apixaban probably has the best safety profile in geriatric patients (≥ 75 years) [20]. Likewise, recent observational studies based on real-world data suggest that DOACs are not associated with an increased bleeding risk compared to VKAs but results appear to depend on the specific DOAC and are heterogeneous across countries [14–18].

The previous evidence on the safety of DOACs in older adults mainly stems from observational evidence and therefore must be interpreted with caution because of the risk of confounding bias. Noticeably, confounding by indication for safety outcomes would mean that patients at higher risk for adverse events when using DOACs would have a lower chance to get a DOAC prescribed and consequently would mean a bias towards the null effect, i.e. would suggest no safety concerns [21].

Our objective was to assess the safety of long-term intake of DOACs in older adults with AF. Our analyses are based on data from RCTs or subgroup analyses from RCTs on older adults (≥ 65 years) to increase the applicability of the results to patients in routine care.

**Methods**

We registered the protocol for this review in PROSPERO: CRD42020187876. All changes to the protocol are explicitly reported in the methods section.

This systematic review was performed according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions [22] and follows the reporting recommendations of the updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [23].

**Eligibility criteria**

**Participants**

Eligible participants must be diagnosed with atrial fibrillation (AF) and above the age of 65 years. We operationalized the age criterion as follows:
• ≥80% of the randomized population aged ≥65 years.
• Subgroup analysis reports on participants aged ≥65 years.

**Intervention**

The intervention group must be treated with any type of non-vitamin K antagonist oral anticoagulant. These include:

- apixaban
- dabigatran
- edoxaban
- rivaroxaban

We only included trials with long-term DOAC treatment, defined as a treatment duration of at least 12 months. This criterion was added during study selection because different from our expectation, we recognized that in some, mainly early phase RCTs DOACs treatment was very short, which is not comparable to routine care. Any dose or regimen was eligible. Trials on DOACs not approved in the European Union before 2020 (e.g., ximelagatran, darexaban, or letaxaban) were excluded.

As comparator, we accepted any active control such as conventional anticoagulation treatment, and no treatment, or placebo treatment. Furthermore, additional antithrombotic treatment in combined regimens (i.e. antiplatelet therapy in addition to warfarin) had to be the same in all groups, so that the groups only differed regarding DOAC treatment.

**Outcomes**

We prioritized all-cause mortality, all-cause hospitalization, and major or clinically relevant bleeding (MCRB) as primary outcomes (critical outcomes in GRADE). Secondary outcomes were any adverse event, discontinuation due to adverse events, renal failure, delirium, and falls (important outcomes). In addition, we extracted data on bleeding according to organ system classification.

We did not consider stroke or systemic embolism because we expected that the effectiveness of DOACs for reducing stroke is stable across age groups [24, 25] and consequently the subgroup effect of age would not shift the benefit-risk ratio.

**Types of studies**

Only RCTs or subgroup analyses of RCTs on the relevant age group were eligible.

**Publication status**
We only included trials published in English or German or with data available in an English language trial registry.

Information sources

The identification of relevant literature comprised two stages.

First, we screened the titles/abstracts of the references of all systematic reviews included in an overview previously prepared by the research group of one member of our review team [24].

Second, we updated the electronic literature searches used in the aforementioned overview. For this purpose, MEDLINE, MEDLINE in Process, and Embase (all via Embase) were searched for studies published from 1st June 2014 onwards. We ran the last search on 9th November 2020.

In addition, we searched the reference lists of all included RCTs and systematic reviews on the same topic. Moreover, we searched ClinicalTrials.gov for ongoing and unpublished trials on 30 June 2020.

Search strategy

The search strategy was prepared by an experienced information specialist in collaboration with clinical experts. The full search is presented in supplement I. The search was limited to English and German. In addition, we limited the search to articles and reviews (i.e., excluded conference abstracts) and excluded case reports, in vitro studies and animal experiments. The search included a search filter for the elderly, a modified generic search filter (in addition to specific terms such as bleeding or mortality) for adverse events and a validated search filter for RCTs [26-28]. The search strategy was reviewed by a second person using the PRESS-checklist and validated by checking if clearly eligible RCTs already known would have been identified [29].

Selection process

Two reviewers independently screened the titles and abstracts of all records identified by the literature search. Next, full-text articles of potentially relevant reports were retrieved and assessed for compliance with the eligibility criteria by two reviewers independently. Disagreements between reviewers were resolved by discussion until consensus.

Multiple reports of the same RCT were merged, so that each trial is the unit of analysis. The study selection process was summarized in an updated PRISMA flow diagram [42].
Data collection process

Descriptive data were extracted by one reviewer and checked for accuracy by a second reviewer. Two reviewers independently identified relevant outcome data by marking the section in the relevant source. Subsequently, one reviewer extracted the data, and a second reviewer checked its correctness. All disagreements were resolved in discussions until consensus.

In case of missing data or inconsistent data on primary outcomes in different sources, we contacted the corresponding author by e-mail.

Data items

Supplement II lists all items for which we extracted data.

We extracted data on outcomes for the last available follow-up, i.e. the longest observation period.

Supplemental to the outcome data, we extracted data on within study subgroup analyses. We only extracted data if the relevant subgroup analysis was pre-specified and a test of interaction was used to quantify the statistical certainty of the subgroup effect [30].

Study risk of bias assessment

We assessed the risk of bias with the revised Cochrane risk-of-bias tool for RCTs (RoB 2 tool) [31]. The RoB 2 tool provides a framework for assessing the risk of bias for one particular outcome that is for each outcome separately.

Effect measures

All considered outcomes were dichotomous. We extracted relative risk ratios from regression analyses (e.g., hazard ratios from a survival analysis) with 95% CIs. If these were not available (e.g., data from trial registries), we extracted raw data on events and number of participants for each group and calculated relative risks.

Synthesis methods

Statistical synthesis method
We pooled data only if RCTs were sufficiently clinically and methodologically homogenous and the p-value of the statistical test for heterogeneity was >0.05. To describe statistical heterogeneity, we calculated prediction intervals and I-square.

We pooled adverse event data separately for each comparator (VKAs, Aspirin only, Placebo) and dose because we assumed, they would have different risks, in particular for bleeding. We calculated systemic adverse events across AF patients (AF-only patients) and AF patients who had a percutaneous coronary intervention (AF-PCI patients), provided the patients were clinically comparable otherwise (e.g. renal function, comorbidity).

Mortality and hospitalization are composite outcomes, to be concrete measures that combine benefits (e.g. stroke reduction) and harms (e.g. bleeding). Therefore, for mortality and hospitalization we combined different comparators because we were interested in the net benefit of DOACs compared to all possible treatments that are applied in routine care. Moreover, we pooled mortality and hospitalization separately for AF and AF-PCI patients because the benefits of DOACs (e.g., stroke prevention) likely differ between AF and AF-PCI patients.

We derived the log standard errors, which are necessary for meta-analysis from the 95% confidence intervals (95% CIs). If more than one distinct subgroup for older adults was available (e.g. 65-74 years and ≥75 years), we pooled the results within one RCT using fixed effect meta-analysis. To combine different RCTs, we performed inverse variance random effects meta-analyses using the Hartung-Knapp method and the Paule–Mandel heterogeneity variance estimator [32, 33]. For outcomes for which only sparse data were available (event rate <5%, zero event studies, less than four RCTs in meta-analysis) we planned to use beta-binomial regression models for sensitivity analyses [34, 35].

We used the R-Package Meta in R 9.4 for the meta-analyses [36]. In case of heterogeneity, we synthesized results across RCTs presenting range of effects of the point estimate of the relative risk ratio.

Subgroup analyses for exploring heterogeneity

We expected that our primary analyses would be mainly based on data from subgroup-analyses, and we had therefore not planned to perform subgroup analyses. However, in some meta-analyses there was statistically significant heterogeneity, and therefore we performed post-hoc subgroup analyses on study level according to agent.

Sensitivity analyses
We planned to perform a sensitivity analysis excluding RCTs at high risk of bias in the randomisation domain.

**Reporting bias assessment**

We planned to assess publication bias by visual inspection of funnel plots for asymmetry, if at least 10 trials for each outcome were available.

We expected adverse events and mortality to be assessed in all RCTs. We considered RCTs/publications specifically on older adults in which mortality, overall adverse events, or discontinuation due to adverse events were not reported (and for which we got no information in response to author requests) susceptible for reporting bias. Bias in selection of the reported results within one trial is a domain of the RoB2 tool (see above). In the RoB2 assessment, we compared the list of outcomes reported in the protocols or methods section with the outcomes reported in the published paper.

**Certainty of evidence assessment**

We rated the certainty of the body of evidence using the GRADE approach (Grading of Recommendations, Assessment, Development and Evaluation). In the GRADE system evidence from RCTs starts as “high-certainty” and the following criteria are applied for downgrading the certainty of evidence by one or two levels [37]:

- Risk of bias
- Imprecision
- Inconsistency
- Indirectness
- Publication bias

The rating of these criteria leads to four levels of the certainty of evidence for each of the prioritized outcomes [38]:

- High-certainty evidence: the review authors have a lot of confidence that the true effect is similar to the estimated effect.
- Moderate-certainty evidence: the review authors believe that the true effect is probably close to the estimated effect.
- Low-certainty evidence: the review authors believe that the true effect might be markedly different from the estimated effect.
• Very low-certainty evidence: the review authors believe that the true effect is probably markedly different from the estimated effect.

One reviewer judged the certainty of the evidence and a second reviewer verified the assessment. Disagreements were resolved by discussion until consensus.

The certainty of evidence and results are presented in ‘Summary of Findings’ (SoF) tables [39]. The SoF tables were prepared using GRADEpro GDT [40]. For estimating the absolute effect, we used absolute risks for the control group based on publications thought to be representative for routine care in western countries [15, 16, 18]. If we could not find a suitable publication for one outcome, we used the risk of the comparator group of included RCTs.

To report the findings in consideration of the certainty of evidence, we used the standardized informative statements suggested by the GRADE working group [41].

The certainty of evidence is expressed with the following statements:

• High-certainty: reduces/increases outcome
• Moderate-certainty: “likely/probably” reduces/increases outcome
• Low-certainty: “may” reduce/increase outcome
• Very low-certainty: the evidence is uncertain

Results

Study selection

Figure 2 shows the study selection according to the PRISMA statement [23]. The initial screening of publications included in the previously published overview [24] identified 87 potentially relevant RCTs (based on 111 trial reports) of which we screened full-text versions. The electronic search provided a total of 845 citations after duplicate removal. Titles/abstracts of these were screened and 40 potentially eligible study reports were identified. The screening of full-text publications yielded ten RCTs (reported in eighteen publications) which met all eligibility criteria [2–9, 42, 43]. The search in ClinicalTrials.gov and the screening of reference lists of included RCTs and relevant systematic reviews did not lead to additional inclusions. A list of excluded studies and the primary reason for exclusion are provided in Supplement III.

We contacted nine authors by e-mail for additional information. Four authors responded, and one provided additional numerical data [44]. In addition, we received results of an analysis of subgroup effects from an individual patient data (IPD) meta-analysis of five of the included RCTs, in response to an author request [2–6, 45].

Study characteristics
The eligible RCTs/subgroup analyses of RCTs (in the following all only called RCTs), included 61,948 participants in total. Table 1 shows the characteristics of the included RCTs (for detailed characteristics see supplemental table IV).

Six RCTs (ARISTOTLE [2, 46], AVERROES [3, 47], ELDERCARE [43], ENGAGE [4, 48, 49], RE-LY [5, 50], and ROCKET [6, 51]) included any patient with AF and three trials (RE-DUAL [7, 52], PIONEER [8, 9], and ENTRUST [42]) were conducted in AF-PCI patients [53]. One RCT was conducted in participants with non-valvular AF on haemodialysis due to end-stage renal disease (Valkyrie [44]).

The median or mean age was 70 years or older. All RCTs included more men than women. In all RCTs, a significant proportion of the study population had an increased risk of bleeding and suffered from reduced renal function. Average BMI/weight was above the normal in most studies but does not reach severe obesity in any RCT.

Two RCTs compared apixaban with either warfarin or aspirin [2, 3], three edoxaban with either placebo, aspirin, or VKA [4, 42, 43], two dabigatran with warfarin [5, 7] and three rivaroxaban with warfarin [6, 8, 44]. In the PCI trials, the patients were treated with antiplatelets in addition to oral anticoagulants [7, 8, 42].

All trials were funded by the pharmaceutical industry.

**Risk of bias of included RCTs**

Table 2 contains the risk of bias assessment for each individual RCT. Results are presented on study level (not outcome level) because in none of the RCTs the risk of bias differed for different outcomes (e.g., bleeding and falls). For five RCTs we assessed the overall risk of bias to be low [44, 46, 48, 50, 51] and for five RCTs we had some concerns regarding the overall risk of bias [9, 42, 43, 47, 52].

**Reporting bias**

We could not prepare funnel-plots because none of the meta-analyses included at least ten studies. Three publications focused on the elderly but did not report mortality or any adverse event [48, 51, 52].

**Effects of DOACs on the elderly**

The results of the meta-analyses and of each individual RCT included in the meta-analyses are shown in the forest-plots (Figs. 2–4 and supplemental figures I and II). Results of the syntheses with certainty of evidence ratings are presented in the Summary of Findings table (Table 3). The RCTs that were not included in the meta-analyses, because they did not match any pre-specified comparison, or because of clinical heterogeneity are presented in supplement V.

**Mortality**

DOACs probably reduce mortality in elderly patients with AF-only (HR 0.89 95% CI 0.78 to 1.02) [7, 43, 46, 47, 50]. Likewise, in the Valkyrie trial, end stage renal disease patients with AF receiving low-dose
rivaroxaban had numerically lower mortality compared to patients receiving VKAs (RR 0.82 95%CI 0.46 to 1.45) [44]. We could not find any RCT that reported mortality in elderly AF-PCI patients.

**Major or clinically relevant bleeding**

In the meta-analyses, there was statistically significant heterogeneity and therefore the results were not pooled across all included RCTs [9, 42, 46, 48, 50–52]. This was true for both, the meta-analysis on low-dose and on high-dose DOACs. To explore this heterogeneity, we performed post-hoc subgroup analyses. We decided to stratify the analyses according to agent because previous systematic reviews and large real-world studies had suggested that dabigatran and rivaroxaban tend to have a higher bleeding risk than apixaban and edoxaban [13, 15, 16, 18, 20, 54].

For low doses, the separate analyses according to agents did not resolve heterogeneity [9, 46, 48, 50, 52]. A common quantitative measure would therefore be misleading and consequently no meta-analysis was performed, and we only compiled a narrative synthesis. According to this, low-dose DOACs likely reduce bleeding compared to VKAs (HR ranged from 0.47 to 1.01). Likewise, in end-stage renal disease patients, low-dose rivaroxaban decreased major bleeding risk numerically compared to VKAs (RR 0.58 95%CI 0.25 to 1.34) [44]. In the ELDERCARE trial low-dose edoxaban increased major bleeding numerically compared to placebo (HR 1.87 95%CI 0.90 to 3.89) [43]. In the AVERROES trial, apixaban increased major bleeding risk numerically compared to aspirin, but 95%CIs overlapped appreciable benefit and harm (1.21 95%CI 0.69 to 2.12) [47].

For high-dose DOACs, the distinct meta-analyses according to agent resolved heterogeneity and we pooled the data. The analyses showed that high-dose edoxaban decreases MCRB risk (HR 0.82 95%CI 0.73 to 0.93) [42, 48], but that high-dose dabigatran or rivaroxaban increase MCRB risk compared to VKAs (HR 1.15 95%CI 1.02 to 1.30) [50–52].

**Subgroup considerations**

Table 4 shows the results of the within study subgroup analyses for age. The subgroup analyses indicate that the positive effect on mortality in favour of DOACs might decrease with age. The MCRB risk appears to increase with age, whereby the effect direction in favour of DOACs might reverse in very old people (about 85–90 years).

Subgroup-analyses for major bleeding according to all AF patients versus AF-PCI patients [8, 42, 52], do not change the results (data not shown). An explorative analysis of bleeding risk according to body part suggested that DOACs increase the risk of gastrointestinal bleeding but reduce the risk of intracranial bleeding numerically (data not shown).

**Secondary outcomes**

Apixaban likely reduces overall hospitalisations (HR 0.84 95%CI 0.76 to 0.93) [46, 47]. In the ELDERCARE trial the difference in hospitalizations was negligible (RR 1.02 95%CI 0.67 to 1.58). We did not find any RCT that reported on hospitalisations in AF-PCI patients. There is no evidence from RCTs in general on
overall adverse events, discontinuation due to adverse events, renal failure, falls or delirium in elderly patients with AF treated with DOACs.

Sensitivity analyses

We performed no sensitivity analysis according to risk of bias because none of the RCTs was assessed to be at high risk of bias or risk of bias in the randomisation domain.

Sensitivity analyses of meta-analyses including < 4 RCTs and few numbers of events were not possible because the beta-binomial model is a one-stage model, which requires data that allow to reconstruct a contingency table, but for almost all RCTs only aggregated data (e.g., HRs) were available.

Discussion

Summary and interpretation in consideration of other evidence

Our systematic review shows that DOACs probably reduce mortality in elderly AF-only patients to a larger extent than VKAs. The findings were consistent across different agents and different doses agree with previous results of RCTs on all age groups, which suggests that the global effectiveness of DOACs in AF is not significantly influenced by age and a positive benefit-risk ratio of DOACs in comparison to VKAs does also exist in the older population with AF-only [13, 25, 45]. In the population with AF, the lower risk for bleeding in the low-dose treatment groups is apparently not counterbalanced by a higher risk for lethal thromboembolic events. In the high-dose treatment groups a significantly higher bleeding risk does exist for dabigatran and rivaroxaban, but not for edoxaban, which might be explained by the different extent of renal elimination.

We found no RCT that reported on mortality for AF-PCI patients, however meta-analyses in the entire population, i.e. not only elderly, showed that mortality in the DOACs group was not statistically significantly higher than in the VKA group [42, 55]. Apparently, in this population, the approach of combining DOACs with only one antiplatelet agent (instead of dual antiplatelet therapy = DAPT) in comparison to the efficacy and safety with VKA plus DAPT results in a lower risk for bleeding, but a higher risk for thromboembolic or coronary events.

Studies based on real-world data showed heterogeneous results for mortality when using DOACs compared to VKAs in AF patients [14–17]. The studies neither distinguished between AF-only and AF-PCI patients nor patients with different heart disease severity in general. Remarkably, in these observational studies, morbidity due to cardiovascular disease was high and more similar to the PCI population than to the AF-only population in our review. The differences in morbidity, in particular the probable differences in proportion of PCI-patients, might be one explanation for the heterogeneous results for the effectiveness of DOACs in Studies based on real-world data and also for the tendency of a weaker impact of DOACs on mortality under routine conditions compared to the RCTs on AF-only patients [14, 15, 55].
Another explanation for the heterogeneous findings could be the type of VKA used. In large real-world studies performed in the USA and Denmark, taking DOACs was associated with fewer deaths compared to VKAs [16, 17]. In contrast, similar studies performed in Germany showed higher mortality compared to VKAs [15]. The reason for this difference could be the different VKA prescribing practices; in the USA, warfarin is mainly, whereas but phenprocoumon is prescribed in Germany. Pharmacological studies showed that for long-term use phenprocoumon is preferable compared to warfarin because phenprocoumon patients more often have an INR in the therapeutic range [56]. Conspicuously, the patterns of mortality and major bleeding risk appear to agree, concrete studies showing higher major bleeding risk tend to show less favourable results for mortality, indicating that at least a part of the differences in mortality might be explained by death as a result of major bleeding.

We found that low-dose DOACs probably decrease MCRB compared to VKA in AF-only and similarly in AF-PCI patients but could not quantify this reduction reliably because of statistical heterogeneity. The heterogeneity could neither be fully explained by subgroup analyses of patient type (AF-only vs AF-PCI) nor by subgroup analysis on drug type. All but one RCT showed reduced MCRB and in one RCT the bleeding rates were comparable between DOAC (dabigatran) and warfarin. In the two RCTs on low-dose dabigatran the PCI trial showed lower major bleeding risk using dabigatran compared to warfarin, which is probably explained by the concomitant therapy with only one antiplatelet agent in the DOAC group and DAPT in the warfarin group. Consistent with real-world studies, apixaban and edoxaban showed the lowest risk for MCRB [15, 16].

Preliminary evidence, showed numerically more MCRB when taking low-dose DOACs compared to aspirin and placebo in AF-only patients [43, 47]. Furthermore, the RCT of low-dose rivaroxaban in AF-only patients with end-stage renal disease provides a hint that the results for MCRB in this population might be similar to the results in the elderly in general, meaning that the current evidence from RCTs does not indicate that in patients with end-stage renal disease DOACs should not be taken in general [44].

For high-dose DOACs the MCRB risk seems to depend on the agent. This seems to be true both for AF-only and AF-PCI patients. Rivaroxaban and dabigatran increased the bleeding risk. In contrast, high-dose edoxaban reduced the MCRB risk. Again, the real-world studies found heterogeneous results for these drugs [14–18]. However, it must be considered that the impact of different doses of DOACs was not analysed in these observational studies. Considering that the quality of evidence for our findings is high and considering results of previous analyses on the influence of dosing, it appears plausible that the different doses are an additional important explanation for the heterogeneous findings on safety of DOACs in the real-world [13].

**Applicability of findings**

Comparing our study population to the patient population from real-world studies confirmed that our population mirrors the patients in routine care quite well. Therefore, none of the RCTs was down-graded due to limited applicability in the certainty of evidence assessment. Notwithstanding, the AF-only patients still tend to be less morbid and comorbid than patients in real-world studies [14–17, 57, 58]. Moreover, all
but two studies that compared DOACs to VKAs used warfarin whereas in many countries other VKAs are mainly prescribed, which limits applicability of the results to these countries [59].

**Quality of the evidence**

The risk of bias of the body of evidence was low. The main limitation of the certainty of evidence for mortality was statistical imprecision. In addition, for low-dose DOACs, the certainty of evidence on MCRB is limited by unexplained heterogeneity.

The evidence in this systematic review is incomplete regarding several safety outcomes including overall adverse events, adverse events leading to discontinuation, and adverse events particularly relevant for the elderly such as delirium or falls.

**Limitations**

One limitation of this systematic review is the literature search. We decided to identify the evidence using previous systematic reviews to speed up the review process. We anticipated that this is a reasonable shortcut considering the very huge number of systematic reviews on DOACs and therefore low risk of missing relevant literature when relying on previous systematic literature searches. In addition, some might argue that the findings are limited because a large part of them stems from subgroup analyses from RCTs on elderly. However, most of the RCTs were very large and additionally stratified the randomisation for age and adjusted the analyses for important prognostic factors. Therefore, it seems improbable that this approach has introduced bias.

**Conclusion**

**Implications for research**

There is an important research gap on overall adverse events and particularly outcomes that are relevant for older adults such as falls, fractures or renal impairment in AF patients in general [60]. In addition, for AF-PCI patients high quality data on mortality is lacking. Studies on these outcomes are necessary for sufficient balancing of the benefits and harms of DOAC use in elderly patients, especially given the low absolute mortality and MCRB risk. Moreover, patient characteristics which might explain the heterogeneity in the real-world, such as very high age, weight, renal function, severe and multi-morbidity, should be further explored because better information on these potential predictors could contribute to an improved individualization of anticoagulation therapy.

**Implications for practice**

No conclusive judgement on the safety of DOACs in older adults is possible because of the lack of RCTs assessing overall adverse events and outcomes relevant in the elderly (e.g., fractures, delirium) [60]. Our data and external evidence from real-world studies suggest that the bleeding risk depends on agent, dose
and age. Moreover, the impact of DOACs on mortality and hospitalization probably depends on patient type (AF-only vs AF-PCI). Similarly, to previous systematic reviews on all age groups, we found that low-dose DOACs probably decrease mortality in older AF-only patients. Moreover, Apixaban and edoxaban are associated with fewer MCRB compared to VKAs [13]. For dabigatran and rivaroxaban, the risk of MCRB varies depending on dose. Moreover, subgroup analyses indicate that in the very old (≥85) the bleeding risk of DOACs in general, but especially for dabigatran and rivaroxaban might be even higher than for VKAs. The uncertainty due to heterogeneous results and the limited impact of DOACs on absolute mortality, clarify once again that the individual anticoagulation treatment choice should cautiously balance the individual patient’s benefit-risk profile, especially in the very old.

List Of Abbreviations

| Abbreviation | Full Form |
|--------------|-----------|
| AF           | Atrial fibrillation |
| DOAC         | Direct oral anticoagulants |
| MCRB         | Major or clinically relevant bleeding |
| PCI          | Percutaneous coronary intervention |
| RCT          | Randomised controlled trial |
| VKA          | Vitamin K antagonists |

Declarations

Funding

This work was part of the project “Updating the PRISCUS list of potentially inappropriate medications for the elderly” funded by the German Federal Ministry of Education and Research (Grant Number: 01KX1812).

Conflicts of interest/Competing interests

KD, SB, AW, NKM, SH, DP, AS, DP, PAT and TM declare that they have no competing interests.

Availability of data and materials

All data generated or analysed in this study are included in this published article [and its supplementary information files]

Code availability

Not applicable.

Authors’ contributions
KD: study selection, data extraction, interpretation of results, writing of manuscript, revision of manuscript

SB: data extraction, interpretation of results, revision of manuscript

AW: study selection, data extraction, interpretation of results, revision of manuscript

NKM: interpretation of results, writing of manuscript

SH: design and conduct of electronic searches

AS: development of study concept, interpretation of results, revision of manuscript

DP: development of study concept, interpretation of results, revision of manuscript

PAT: development of study concept, interpretation of results, revision of manuscript

TM: development of study concept, study selection, data extraction, statistical analysis, interpretation of results, writing of manuscript

**Ethics approval and consent to participate**

Not applicable.

**Consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Acknowledgements**

Not applicable.

**Compliance with Ethical Standards**

**Disclosure of potential conflicts of interest**

KD, SB, AW, NKM, SH, DP, AS, DP, PAT and TM declare that they have no conflicts interests.

**Research involving Human Participants and/or Animals**

This research does not involve humans or animals.

**Informed consent**

Not applicable.
References

1. Mekaj YH, Mekaj AY, Duci SB, Miiftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77.

2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

3. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.

4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špínar J. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

7. Cannon CP, Bhatt DL, Oldgren J, Lip GY, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.

8. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.

9. Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation. 2017;135(4):323–33.

10. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan G-A, Dilaveris PE. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal 2020.

11. January Craig T, Wann LS, Alpert Joseph S, Calkins H, Cigarroa Joaquin E, Cleveland Joseph C, Conti Jamie B, Ellinor Patrick T, Ezekowitz Michael D Field. Michael E et al: 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2014;64(21):e1–76.
12. Chen A, Stecker E, Bruce AW. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. Journal of the American Heart Association. 2020;9(13):e017559.

13. López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.

14. Gieling E, de Vries F, Williams R, van Onzenoort HAW, de Boer A, ten Cate V, Kramers C, Burden A. Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. International Journal of Clinical Pharmacy. 2019;41(6):1536–44.

15. Paschke LM, Klimke K, Altiner A, von Stillfried D, Schulz M. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. BMC Med. 2020;18(1):254.

16. Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, Hu M, Illoh O, Wei Y, Goulding MR, et al. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. Am J Med. 2019;132(5):596–604.e511.

17. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61(22):2264–73.

18. Souverein PC, van den Ham HA, Huerta C, Merino EM, Montero D, León-Muñoz LM, Schmiedl S, Heeke A, Rottenkolber M, Andersen M, et al: Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. Br J Clin Pharmacol 2020.

19. Committee for Medicinal Products for Human Use (CHMP). Assessment report INN/active substance: direct oral anticoagulants (DOACs). In: Assessment report. Edited by EMA; 26 March 2020.

20. Grymonprez M, Steurbaut S, De Backer TL, Petrovic M, Lahousse L. Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020;11:583311.

21. Safieddine M, Chapelle C, Ollier E, Ferdynus C, Bertoletti L, Mismetti P, Cucherat M, Laporte S. Compared to randomized studies, observational studies may overestimate the effectiveness of DOACs: a metaepidemiological approach. J Clin Epidemiol. 2021;130:49–58.

22. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019.

23. Page MJ, Moher D, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, Shamseer L, Tetzlaff J, Akl E, Brennan SE: PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. 2020.

24. Sommerauer C, Schlender L, Krause M, Weißbach S, Rieckert A, Martinez YV, Reeves D, Renom-Guiteras A, Kunnamo I, Sönnichsen A. Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults – a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. BMC Geriatrics. 2017;17(1):223.
25. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.

26. Wong SSL, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc. 2006;94(1):41–7.

27. Concepts de stratégies de recherche. Personnes âgées https://extranet.santecom.qc.ca/wiki/!biblio3s/doku.php?id=concepts:personnes_agees#dokuwiki__top.

28. Concepts de stratégies de recherche. Effets secondaires https://extranet.santecom.qc.ca/wiki/!biblio3s/doku.php?id=concepts:effets-secondaires.

29. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40–6.

30. Schandelmaier S, Chang Y, Devasenapathy N, Devji T, Kwong JSW, Colunga Lozano LE, Lee Y, Agarwal A, Bhatnagar N, Ewald H, et al. A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses. J Clin Epidemiol. 2019;113:159–67.

31. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:i4898.

32. Deeks JJ, Higgins JP, Altman DG, Group CSM. Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions 2019:241–284.

33. Langan D, Higgins JPT, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, Viechtbauer W, Simmonds M. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. 2019;10(1):83–98.

34. Mathes T, Kuss O. A comparison of methods for meta-analysis of a small number of studies with binary outcomes. Research Synthesis Methods. 2018;9(3):366–81.

35. Kuss O. Statistical methods for meta-analyses including information from studies without any events—add nothing to nothing and succeed nevertheless. Stat Med. 2015;34(7):1097–116.

36. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–60.

37. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.

38. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, Alper BS, Meerpohl JJ, Murad MH, Ansari MT, et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4–13.

39. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J
Clin Epidemiol. 2011;64(4):383–94.

40. GDT. GRADEpro guideline development tool. [Accessed on September 2020]. In.: gradepro.org.

41. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, Brignardello-Petersen R, Carrasco-Labra A, De Beer H, Hultcrantz M. GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126–35.

42. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. The Lancet. 2019;394(10206):1335–43.

43. Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, Eshima K, Tanizawa K, Fukuzawa M, Hayashi T. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. New England Journal of Medicine 2020.

44. De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie Study. J Am Soc Nephrol. 2020;31(1):186–96.

45. COMBINE-AF investigators. Non-vitamin K antagonists oral anticoagulants versus warfarin in atrial fibrillation, individual patient data from pivotal trials In: European Society for Cardiology Congress 2020. 2020.

46. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European heart journal. 2014;35(28):1864–72.

47. Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, Lanas F, Yusuf S, Hart RG. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing. 2016;45(1):77–83.

48. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF–TIMI 48 trial. Journal of the American Heart Association. 2016;5(5):e003432.

49. Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, Oldgren J, Nakamya J, Wang J, Connolly SJ. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103(13):1015–23.

50. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.

51. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W. Efficacy and safety of rivaroxaban compared with warfarin among elderly
patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138–46.

52. Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, et al. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial). Am J Cardiol. 2020;125(5):735–43.

53. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103(01):13–28.

54. Fernandez MM, Wang J, Ye X, Kwong WJ, Sherif B, Hogue S, Sherrill B. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ≥ 2. SAGE Open Med. 2015;3:2050312115613350.

55. Al Said S, Alabed S, Kaier K, Tan AR, Bode C, Meerpohl JJ, Duerschmied D. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis. Cochrane Database of Systematic Reviews 2019(12).

56. Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost. 2008;100(6):1052–7.

57. Souverein PC, van den Ham HA, Huerta C, Merino EM, Montero D, León-Muñoz LM, Schmiegel S, Heeke A, Rottenkolber M, Andersen M, et al: Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. British Journal of Clinical Pharmacology, n/a(n/a).

58. Nielsen PB, Skjøth F, Søgaard M, Kjælgaard JN, Lip GYH, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.

59. Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, Zamorano JL, Kirchhof P. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost. 2014;111(5):833–41.

60. Thürmann PA. Clinical studies in geriatric population. Drug Discovery and Evaluation: Methods in Clinical Pharmacology 2020:417–424.

**Tables**

Table 1
| Study | Patients (Intervention/Comparison) | Intervention and Comparison | Available Outcomes |
|------|----------------------------------|-----------------------------|-------------------|
| **VKA comparison** | | | |
| **ARISTOTLE** | Patient characteristics 65 to <75y/≥75y Age group n(%) 65 to <75 years 7052(39) ≥75 years 5678(31) Female n(%) 2525(35.8)/2396(42.2) Weight [kg] Mean(SD) 84.1(19.2)/76.5(16.4) HAS-BLED-Score n(%) 1 2008(28.5)/1322(23.3) 2 3078(43.6)/2442(43.0) ≥3 1966(27.9)/1914(33.7) Renal function by Cockcroft–Gault, n(%) Normal (>80 ml/min) 2761(39.2)/597(10.5) Mild impairment (>50 to 80 ml/min) 3511(49.8)/2922(51.5) Moderate impairment (>30 to 50 ml/min) 713(10.1)/1906(33.6) Severe impairment (≤30 ml/min) 40(0.6)/222(3.9) | **Intervention** Apixaban, 5 mg twice daily **Dose reduction** 2.5 mg twice daily for patients with two or more of the following factors: age ≥80 years, bodyweight ≤60 kg, serum creatinine ≥133 μmol/L (≥1.5 mg/dL) **Comparison** Dose-adjusted (INR 2–3) warfarin | Mortality Major or clinically relevant bleeding Hospitalisation |
| **ENGAGE AF-TIMI 48** | Patient characteristics age category 65 - 74y/≥75y Age [y] Median(IQR) 70(67.0–72.0)/79(76.0–82.0) Female n(%) 2753(39)/3777(45) Weight [kg] Median(IQR) 83.0(71.0–95.7)/76.0(65.9–86.5) HAS-BLED-Score ≥3 n(%) 4129(58)/4779(56) Renal function: CrCl (mL/min) Median(IQR) 74(60–90)/56(45–69) | **Intervention 1** Edoxaban 60 mg once-daily **Intervention 2** Edoxaban 30 mg once-daily **Dose reduction** The dose of edoxaban was reduced by 50% if any of the following factors were present at the time of randomization or during the study: calculated CrCl of ≤50 mL/min using the Cockcroft-Gault formula, body weight ≤60 kg, or the concomitant use of potent P-glycoprotein inhibitors. **Comparison** Dose-adjusted (INR 2–3) warfarin | Major or clinically relevant bleeding |
| **RE-DUAL PCI** | Patient characteristics Age [y] Mean(SD) 79.3(3.6) | **Intervention 1** Dabigatran etexilate 110 mg twice daily plus either clopidogrel or ticagrelor | Mortality Major or clinically relevant bleeding |
### RE-LY
#### Patient characteristics IG1/IG2/CG*
- **Age [y]**: Mean(SD) 71.4(8.6)/71.5(8.8)/71.6(8.6)
- **Female n(%)**: 2150(35.7)/2236(36.8)/2213(36.7)
- **Weight [kg]**: Mean(SD) 82.9(19.9)/82.5(19.4)/82.7(19.7)
- **HAS-BLED-Score**: NR
- **Renal function**: NR

#### Intervention 1
- Dabigatran 110 mg twice daily

#### Intervention 2
- Dabigatran 150 mg twice daily

#### Comparison
Warfarin + aspirin (≤100 mg daily, 1 month when a bare-metal stent was used, and for 3 months when a drug-eluting stent was used) + either clopidogrel or ticagrelor (warfarin triple)

#### Dose reduction
Elderly patients in non-US countries (≥ 80 years) or Japan (≥ 70 years) were randomized to receive dabigatran 110 mg dual or warfarin triple therapy, whereas younger patients in non-US countries (< 80 years) and Japan (< 70 years), and all US patients irrespective of age, were randomized to dabigatran 110 mg dual, dabigatran 150 mg dual, or warfarin triple therapy

### ROCKET-AF
#### Patient characteristics IG/CG*
- **Age [y]**: Median(IQR) 79(76-82)/79(76-82)
- **Female n(%)**: 1446(46.4)/1432(46.1)
- **BMI [kg/m²]**: Median(IQR) 27.4(24.7-30.7)/27.2(24.6-30.4)
- **HAS-BLED-Score**: NR
- **Renal function, CrCl [ml/min]**: Median(IQR) 55(44-68)/55(44-68)

#### Intervention
- Fixed-dose rivaroxaban 20 mg daily

#### Dose reduction
- 15 mg daily in patients with a CrCl of 30 to 49 ml/min

#### Comparison
Dose-adjusted (INR 2–3) warfarin

### PIONEER AF PCI
#### Patient characteristics IG/CG*
- **Age [y]**: Median(IQR)
- **Female n(%)**: 322(31.4)
- **Weight / BMI [kg/m²]**: NR
- **Modified HAS-BLED-Score**: Mean(SD) 3.0(0.6)
- **Renal function**: NR

#### Intervention
- Dabigatran etexilate 150 mg twice daily plus either clopidogrel or ticagrelor (dabigatran dual)
| Patient characteristics IG/CG* | Intervention | Comparison |
|---------------------------------|--------------|------------|
| Age [y] Median(IQR) | Edoxaban 60 mg once-daily plus clopidogrel, 75 mg once-daily (or prasugrel, 5 mg or 10 mg once daily or ticagrelor, 90 mg twice daily) | Major bleeding |
| Age [y] Median(IQR) | Edoxaban 30 mg once daily (for patients with any of the following characteristics: moderate or severe renal impairment (calculated CrCl 15-50 mL/min), bodyweight ≤ 60 kg, or concurrent use of specific potent P-glycoprotein inhibitors (cyclosporine, dronedarone, erythromycin, or ketoconazole)) | Mortality Major or clinically relevant bleeding |
| Female n(%) | | |
| 194(26) / 192(25) | | |
| Weight [kg] Median(IQR) | | |
| 80(71-93) / 83(72-94) | | |
| HAS-BLED-Score Median(IQR) | | |
| 3.0(2.0-3.0) / 3.0(2.0-3.0) | | |
| Renal function, CrCl [mL/min] Median(IQR) | | |
| 71.8(53.7-91.1) / 71.7(54.0-90.9) | | |

**Rivaroxaban, 2.5 mg twice daily plus background DAPT (low-dose aspirin (75 to 100 mg per day) and clopidogrel, 75 mg once daily (or ticagrelor, 90 mg twice daily or prasugrel, 10 mg once daily in ≤ 15% of participants) for a prespecified duration of 1, 6, or 12 months**

Participants who received the treatment for 1 or 6 months then received rivaroxaban, 15 mg once daily (or 10 mg once daily if they had moderate renal impairment) plus background single antiplatelet therapy with low-dose aspirin (75 to 100 mg per day) for the remainder of the 12-month treatment period.

**Comparison**

Dose adjusted (INR 2.0-3.0) warfarin once daily plus background DAPT with low-dose aspirin (75 to 100 mg per day) and clopidogrel, 75 mg once daily (or ticagrelor, 90 mg twice daily or prasugrel, 10 mg once daily in ≤ 15% of participants) for a prespecified duration of 1, 6, or 12 months.

Participants who received the treatment for 1 or 6 months then received dose adjusted (INR 2.0-3.0) warfarin once daily plus background single antiplatelet therapy with low-dose aspirin (75 to 100 mg per day) for the remainder of the 12-month treatment period.
### Valkyrie study

**Only patients with end-stage renal disease**

**Patient characteristics IG/CG**

| Age [y] Median(IQR) | 79.9(74.4-83.9)/80.3(71.5-84.3) |
| Female n(%) | 11(23.9)/19(43.2) |
| BMI [kg/m$^2$] Median (IQR) | 24.7(22.0-27.5)/25.6(22.3–30.4) |
| HAS-BLED-Score Mean(SD) | 4.6(0.8)/4.7(0.9) |

**Intervention**
Rivaroxaban 10 mg daily

**Dose reduction**
NR

**Comparison**
Adjusted dose (INR 2-3) VKA

**Mortality**
Major or clinically relevant bleeding

---

### AVERROES

**Patient characteristics**

| Age [y] Mean(SD) | 80.4(4.3)/80.4(4.2) |
| Female n(%) | 433(47.8)/486(50.0) |
| BMI [kg/m$^2$] Mean(SD) | 26.9(4.9)/27.0(4.7) |
| HAS-BLED-Score Mean(SD) | 2.3(0.9)/2.4(0.9) |

**Intervention**
Apixaban 5 mg twice daily

**Dose reduction**
2.5 mg twice daily for patients with two or more of the following factors: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dl or 133 μmol/l

**Comparison**
Aspirin 81 - 324 mg daily

**Mortality**
Major or clinically relevant bleeding

**Hospitalisation**

---

### ELDERCARE-AF

**Patient characteristics IG/CG**

| Age [y] Mean(SD) | 86.7(4.2)/86.4(4.3) |
| Female n(%) | 280(56.9)/285(57.9) |
| BMI [kg/m$^2$] Mean(SD) | 22.1(3.6)/22.2(3.8) |
| HAS-BLED score Mean(SD) | 2.3(0.9)/2.4(0.9) |

**Intervention**
Edoxaban, 15 mg, once daily

**Dose reduction**
NR

**Comparison**
Placebo

**Mortality**
Major or clinically relevant bleeding

**Minor bleeding**

**Discontinuation due to adverse events**

---

Dose-adjusted (INR 2.0-3.0) VKA plus clopidogrel, 75 mg once daily (or prasugrel, 5 mg or 10 mg once daily or ticagrelor, 90 mg twice daily) for 12 months and aspirin (100 mg once daily) for a minimum of 1 month and up to 12 months.
### Renal function: CrCl [ml/min]

| Mean(SD) | 36.3(14.3)/36.2(14.5) |

Y: years; n: number; SD: Standard deviation; HAS-BLED Score: HAS-BLED score reflects the risk of Major or clinically relevant bleeding in patients with atrial fibrillation who are receiving anticoagulant therapy, with values ranging from 0 to 9 and with higher scores indicating greater risk; INR: international normalized ratio; IQR: interquartile range; CrCl: Creatinine Clearance; IG: intervention group; CG: comparison group; NR: not reported; DAPT: dual antiplatelet therapy; VKA: vitamin K antagonist

*includes patients aging < 65 years because demographics were not reported for the elderly subgroup separately

**Clinically significant bleeding: major, minor or bleeds requiring medical attention

#### Table 2

| Study ID | Randomization process | Deviations from intended interventions | Missing outcome data | Measurement of the outcome | Selection of the reported result | Overall |
|----------|-----------------------|----------------------------------------|----------------------|----------------------------|----------------------------------|---------|
| ARISTOTLE | +                     | +                                      | +                    | +                          | +                                | +       |
| AVERROES | +                     | +                                      | ?                    | +                          | +                                | !       |
| ENGAGE   | +                     | +                                      | +                    | +                          | +                                | +       |
| RE-LY    | +                     | +                                      | +                    | +                          | +                                | +       |
| ROCKET   | +                     | +                                      | +                    | +                          | +                                | +       |
| ENTRUST  | +                     | ?                                      | +                    | +                          | !                                | !       |
| PIONEER  | +                     | ?                                      | ?                    | +                          | ?                                | !       |
| RE-DUAL  | +                     | ?                                      | +                    | +                          | ?                                | !       |
| ELDERCARE| +                     | +                                      | +                    | +                          | !                                | !       |
| Valkyrie | +                     | +                                      | +                    | +                          | +                                | +       |

- Green circle: + Low risk
- Yellow circle: ? Some concerns
- Red circle: - High risk

#### Table 3
**DOACs compared to any control for atrial fibrillation in older adults**

| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | % of participants (studies) | Certainty of the evidence (GRADE) | Comments |
|----------|----------------------------------------|--------------------------|----------------------------|-----------------------------------|----------|
| Mortality AF (follow up: range 13.2 months to 24 months) | 50 per 1,000 | 45 per 1,000 (39 to 51) | HR 0.89 (0.78 to 1.02) | 19.478 (4 RCTs) | ▫▫▫▫ MODERATE | Rated down one level for imprecision |
| Hospitalization AF (follow up: range 1.1 to 1.8) | 34 per 1,000 | 29 per 1,000 (26 to 32) | HR 0.84 (0.76 to 0.93) | 14.628 (2 RCTs) | ▫▫▫▫ HIGH |

**DOACs compared to VKA in older adults**

| Major or clinically relevant bleeding, low-dose (follow up: range 14 months to 33.6 months) | 150 per 1,000 | 103 per 1,000 (74 to 151) | HR ranged from 0.47 to 1.01 | 24.997 (5 RCTs) | ▫▫▫▫ MODERATE | Rated down one level for one level for inconsistency |
| Major or clinical relevant bleeding, high-dose, subgroup Edoxaban (follow up: range 1 years to 2.8 years) | 150 per 1,000 | 125 per 1,000 (112 to 140) | HR 0.82 (0.73 to 0.93) | 16.668 (2 RCTs) | ▫▫▫▫ HIGH |
| Major or clinical relevant bleeding, high-dose, subgroup Dabigatran or Rivaroxaban (follow up: range 14 months to 23.3 months) | 150 per 1,000 | 170 per 1,000 (153 to 190) | HR 1.15 (1.02 to 1.30) | 22.387 (3 RCTs) | ▫▫▫▫ HIGH |

| Adverse events (any) | No trial reported on this outcome | (0 RCTs) | - |
| Discontinuation due to adverse events | No trial reported on this outcome | (0 RCTs) | - |
| Renal failure | No trial reported on this outcome | (0 RCTs) | - |
| Falls | No trial reported on this outcome | (0 RCTs) | - |
| Delirium | No trial reported on this outcome | (0 RCTs) | - |
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | % of participants (studies) | Certainty of the evidence (GRADE) | Comments |
|----------|-------------------------------------|-------------------------|-----------------------------|---------------------------------|----------|
| Risk with any control | Risk with DOACs | |

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; HR: Hazard Ratio

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Table 4
| Study                        | Hazard ratio (95%CI)                                                                 | p-value of interaction test |
|------------------------------|--------------------------------------------------------------------------------------|----------------------------|
| **Mortality**                |                                                                                      |                            |
| ARISTOTLE                    | Age < 65: 1.07 (0.84 to 1.35)                                                        | 0.43                       |
|                              | Age 65-75: 0.77 (0.64 to 0.94)                                                        |                            |
|                              | Age ≥ 75: 0.91 (0.77 to 1.07)                                                         |                            |
| AVERROES                     | Age < 75: 0.99 (0.68 to 1.44)                                                        | 0.20                       |
|                              | Age ≥ 75: 0.71 (0.50 to 0.99)                                                         |                            |
|                              | Age < 85: 0.79 (0.60 to 1.04)                                                         | 0.88                       |
|                              | Age ≥ 85: 0.80 (0.44 to 1.45)                                                         |                            |
| RE-LY                        | **High dose**                                                                         | 0.014                      |
|                              | Age < 75: 0.77 (0.64 to 0.93)                                                         |                            |
|                              | Age 75-79: 0.82 (0.63 to 1.07)                                                        |                            |
|                              | Age 80-84: 1.16 (0.87 to 1.55)                                                        |                            |
|                              | Age ≥ 85: 1.15 (0.74 to 1.79)                                                         |                            |
|                              | **Low dose**                                                                          | 0.026                      |
|                              | Age < 75: 0.82 (0.68 to 0.98)                                                         |                            |
|                              | Age 75-79: 0.86 (0.66 to 1.11)                                                        |                            |
|                              | Age 80-84: 1.09 (0.80 to 1.47)                                                        |                            |
|                              | Age ≥ 85: 1.37 (0.89 to 2.11)                                                         |                            |
| Individual patient data meta-analysis (RE-LY, ROCKET, AVERROES, ARISTOTLE, ENGAGE) | HR (smaller favours DOACS) decrease with age                                           | 0.079                      |
| **Major or clinical relevant bleeding** |                                                                                  |                            |
| ARISTOTLE                    | Age < 65: 0.78 (0.55 to 1.11)                                                         | 0.63                       |
|                              | Age 65-75: 0.71 (0.56 to 0.89)                                                        |                            |
|                              | Age ≥ 75: 0.64 (0.52 to 0.79)                                                         |                            |
| AVERROES                     | Age < 75: 1.14 (0.58 to 2.30)                                                         | 0.90                       |
|                              | Age ≥ 75: 1.21 (0.69-2.12)                                                           |                            |
|                              | Age < 85: 1.21 (0.74 to 1.99)                                                         | 0.65                       |
|                              | Age ≥ 85: 0.96 (0.38 to 2.39)                                                         |                            |
| ELDERCARE                    | Age ≤ 85: 5.31 (0.62 to 45.21)                                                        | Not reported               |
|                              | Age ≥ 86: 1.49 (0.67 to 3.29)                                                         |                            |
| ENGAGE                       | **High dose**                                                                         | 0.78                       |
|                              | Age < 65: 0.81 (0.58 to 1.12)                                                         |                            |
|                              | Age 65-74: 0.75 (0.60 to 0.94)                                                        |                            |
|                              | Age ≥ 75: 0.83 (0.70 to 0.99)                                                         |                            |
|                              | **Low dose**                                                                          | 0.75                       |
|                              | Age < 65: 0.40 (0.27 to 0.61)                                                         |                            |
|                              | Age 65-74: 0.48 (0.37 to 0.62)                                                        |                            |
|                              | Age ≥ 75: 0.47 (0.38 to 0.58)                                                         |                            |
| RE-LY                        | **High dose**                                                                         | <0.001                     |
|                              | Age < 75: 0.70 (0.57 to 0.86)                                                         |                            |
|                              | Age 75-79: 1.04 (0.81 to 1.35)                                                        |                            |
|                              | Age 80-84: 1.41 (1.02 to 1.94)                                                        |                            |
|                              | Age ≥ 85: 1.22 (0.74 to 2.02)                                                         |                            |
|                              | **Low dose**                                                                          | <0.001                     |
|                              | Age < 75: 0.62 (0.50 to 0.77)                                                         |                            |
|                              | Age 75-79: 0.93 (0.71 to 1.21)                                                        |                            |
|                              | Age 80-84: 1.18 (0.84 to 1.65)                                                        |                            |
|                              | Age ≥ 85: 1.01 (0.59 to 1.73)                                                         |                            |
| Study            | Age Group | HR (95% CI)      | p-value |
|------------------|-----------|------------------|---------|
| ROCKET-AF        | Age < 75  | 0.96 (0.78 to 1.19) | 0.336   |
|                  | Age ≥ 75  | 1.11 (0.92 to 1.34) |         |
| Individual patient data meta-analysis (RE-LY, ROCKET, AVERROES, ARISTOTLE, ENGAGE) | HR (smaller favours DOACS) increases with age. HR <1 (favours) DOACs until 90 years and reverses (>1 favours VKAs) thereafter | 0.031 |
| ENTRUST          |           | HR (smaller favours DOACs) slightly increases with age | 0.914   |
| RE-DUAL          | **High dose** | Age < 75: 0.57 (0.44 to 0.74) | 0.001   |
|                  |           | Age ≥ 75: 1.21 (0.83 to 1.77) |         |
|                  | **Low dose** | Age < 75: 0.67 (0.51 to 0.89) | 0.012   |
|                  |           | Age ≥ 75: 0.40 (0.30 to 0.54) |         |
| PINOEER          | **High Dose** | Age < 65: 0.56 (0.41 to 0.77) | 0.712   |
|                  |           | Age ≥ 65: 0.62 (0.42 to 0.90) |         |
|                  | **High Dose** | Age < 65: 0.57 (0.34 to 0.98) | 0.889   |
|                  |           | Age ≥ 65: 0.60 (0.46 to 0.78) |         |
|                  | **Low Dose** | Age < 65: 0.61 (0.45 to 0.82) | 0.753   |
|                  |           | Age ≥ 65: 0.66 (0.45 to 0.95) |         |
|                  | **Low Dose** | Age < 65: 0.70 (0.43 to 1.16) | 0.678   |
|                  |           | Age ≥ 65: 0.62 (0.47 to 0.81) |         |

**Figures**
Figure 1

PRISMA Flow-diagram

Figure 2

Left image: Mortality AF (n=19.478). Right image: Major bleeding low dose (n=24.997).
Figure 3

Major bleeding high dose edoxaban (n=16,668)

Figure 4

Risk of Bias legend
A: Randomization process
B: Deviations from intended interventions
C: Missing outcome data
D: Measurement of the outcome
E: Selection of the reported result
F: Overall
Major bleeding high dose dabigatran and rivaroxaban (n=22,387)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementfinal.docx